Datavant and Verge Genomics announced a strategic alliance to unlock the value of pharmaceutical datasets to accelerate drug discovery and development.
Datavant partners with a wide range of healthcare organizations to aggregate and integrate datasets, with over 100 clinical datasets reflecting over 150 million unique patients integrated to date. This is complementary to Verge's proprietary machine learning algorithms, drug discovery engine, and patient database. The collaboration aims to connect the full stack of data from early discovery to clinical development and apply machine learning to identify breakthrough opportunities and insights for clinical trial design and interpretation.
This alliance marks the third data partnership Verge has struck in the last six months and its first expansion into the pharmaceutical data landscape.
Roivant Sciences, with the investment support of SoftBank Vision Fund and Founders Fund, spun out Datavant in September 2017 as part of its goal to reduce the time and cost of the drug development process.
"At Verge, we believe that breaking down the barriers that exist between industry, academia, computation and biology is critical to fully realizing the potential of AI in drug discovery," said Alice Zhang, CEO of Verge Genomics. "Our partnership with Datavant advances this mission by opening up new data opportunities previously siloed within pharmaceutical companies."